13 November 2019 - identification of new and highly selective inhibitors of histone deacetylase 6
The “Journal of Medicinal Chemistry” publishes a paper on the identification of new and highly selective inhibitors of histone deacetylase 6 (HDAC6) by the Italfarmaco drug discovery team.
Read more
14 October 2019 - INTERNATIONAL MASTER IN PHARMACEUTICAL MEDICINE
Read more
10 September 2019 - World Drug Safety Congress Europe, 10-11 September 2019, Amsterdam
Invited speaker: Margherita D’Antuono, Corporate Pharmacovigilance Director, EU QPPV Italfarmaco S.p.A.
Read more
07 September 2019 - Bring your light for the World Duchenne Awareness Day
Italfarmaco is devoted to bring the light of hope into the world of Duchenne by committing to develop drugs to slow down the disease progression...
Read more
06 June 2019 - Award Ceremony of Le Fonti Awards, June 6th 2019
Award obtained:
Italfarmaco, Excellence of the Year Innovation & Leadership R&D Pharmaceutical Sector for being an Italian excellence in the pharmaceutical sector.
Read more
29 March 2019 - Italfarmaco Group is pleased to announce the marketing of GhemaXan, the first biosimilar of Enoxaparin Sodium developed and produced in Italy
Read more
25 February 2019 - Italfarmaco launches NUPERAL in Italy, the first drug as fixed combination of doxilamine succinate and pyridoxine hydrochloride authorized for the symptomatic treatment of nausea and vomiting during pregnancy
Read more
20 February 2019 - Gordon Research Conference on Cancer Genetics and Epigenetics
Read more
31 January 2019 - Italfarmaco rafforza la sua presenza nelle malattie rare con il lancio della specialità medicinale VOTUBIA
Read more
09 November 2018 - TRiNDS and Italfarmaco Announce US Patient Advocacy Partnership for EPIDYS Trial of Givinostat for Duchenne Muscular Dystrophy
Read more